Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Med Intensiva ; 46(2): 81-89, 2022 Feb.
Artigo em Espanhol | MEDLINE | ID: mdl-34545260

RESUMO

The COVID-19 pandemic has led to the admission of a high number of patients to the ICU, generally due to severe respiratory failure. Since the appearance of the first cases of SARS-CoV-2 infection, at the end of 2019, in China, a huge number of treatment recommendations for this entity have been published, not always supported by sufficient scientific evidence or with methodological rigor necessary. Thanks to the efforts of different groups of researchers, we currently have the results of clinical trials, and other types of studies, of higher quality. We consider it necessary to create a document that includes recommendations that collect this evidence regarding the diagnosis and treatment of COVID-19, but also aspects that other guidelines have not considered and that we consider essential in the management of critical patients with COVID-19. For this, a drafting committee has been created, made up of members of the SEMICYUC Working Groups more directly related to different specific aspects of the management of these patients.

2.
Med Intensiva (Engl Ed) ; 46(2): 81-89, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-34903475

RESUMO

The COVID-19 pandemic has led to the admission of a high number of patients to the ICU, generally due to severe respiratory failure. Since the appearance of the first cases of SARS-CoV-2 infection, at the end of 2019, in China, a huge number of treatment recommendations for this entity have been published, not always supported by sufficient scientific evidence or with methodological rigor necessary. Thanks to the efforts of different groups of researchers, we currently have the results of clinical trials, and other types of studies, of higher quality. We consider it necessary to create a document that includes recommendations that collect this evidence regarding the diagnosis and treatment of COVID-19, but also aspects that other guidelines have not considered and that we consider essential in the management of critical patients with COVID-19. For this, a drafting committee has been created, made up of members of the SEMICYUC Working Groups more directly related to different specific aspects of the management of these patients.


Assuntos
COVID-19 , Estado Terminal/terapia , Humanos , Unidades de Terapia Intensiva , Pandemias , SARS-CoV-2
3.
Med Intensiva ; 35 Suppl 1: 33-7, 2011 Nov.
Artigo em Espanhol | MEDLINE | ID: mdl-22309750

RESUMO

Severe acute pancreatitis (SAP) causes local and systemic complications leading to high catabolic, hypermetabolic and hyperdynamic stress states with marked morbidity and mortality. In the last decade, nutritional support has become a key element in the treatment of SAP. Thus, specialized nutrition is indicated from admission, with enteral nutrition being preferred to parenteral nutrition. Enteral nutrition should be initiated early using infusion through the jejunum beyond the ligament of Treitz to minimize pancreatic stress. There are no specific studies that establish the type of diet to be used but experts recommend the use of polymeric diets. Parenteral nutrition, without a specific formula, is indicated in patients with SAP who are intolerant to enteral nutrition or when the clinical signs of pancreatitis are exacerbated or aggravated by enteral nutrition. Even so, a minimal level of enteral infusion should be maintained to preserve the trophic effect of the intestinal mucosa. In the last few years, several studies of the administration of immunomodulatory diets in patients with SAP have been carried out to demonstrate their effects on the course of the disease. However, there are few clear recommendations on the prognostic benefits of pharmaconutrient enriched diets in these patients. There is substantial scientific evidence suggesting that the only clear indication for pharmaconutrition in patients with SAP is parenteral glutamine administration, which is recommended by all clinical guidelines with distinct grades of evidence.


Assuntos
Cuidados Críticos , Nutrição Enteral/normas , Pancreatite/terapia , Nutrição Parenteral/normas , Sociedades Médicas/normas , Sociedades Científicas/normas , Doença Aguda , Cuidados Críticos/métodos , Estado Terminal/terapia , Nutrição Enteral/efeitos adversos , Nutrição Enteral/métodos , Alimentos Formulados , Glutamina/administração & dosagem , Glutamina/uso terapêutico , Humanos , Pancreatite/metabolismo , Nutrição Parenteral/métodos , Nutrição Parenteral Total , Prebióticos , Probióticos/administração & dosagem , Prognóstico , Espanha , Fatores de Tempo
4.
Nutr Hosp ; 26 Suppl 2: 32-6, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22411516

RESUMO

Severe acute pancreatitis (SAP) causes local and systemic complications leading to high catabolic, hypermetabolic and hyperdynamic stress states with marked morbidity and mortality. In the last decade, nutritional support has become a key element in the treatment of SAP. Thus, specialized nutrition is indicated from admission, with enteral nutrition being preferred to parenteral nutrition. Enteral nutrition should be initiated early using infusion through the jejunum beyond the ligament of Treitz to minimize pancreatic stress. There are no specific studies that establish the type of diet to be used but experts recommend the use of polymeric diets. Parenteral nutrition, without a specific formula, is indicated in patients with SAP who are intolerant to enteral nutrition or when the clinical signs of pancreatitis are exacerbated or aggravated by enteral nutrition. Even so, a minimal level of enteral infusion should be maintained to preserve the trophic effect of the intestinal mucosa. In the last few years, several studies of the administration of immunomodulatory diets in patients with SAP have been carried out to demonstrate their effects on the course of the disease. However, there are few clear recommendations on the prognostic benefits of pharmaconutrient enriched diets in these patients. There is substantial scientific evidence suggesting that the only clear indication for pharmaconutrition in patients with SAP is parenteral glutamine administration, which is recommended by all clinical guidelines with distinct grades of evidence.


Assuntos
Estado Terminal/terapia , Apoio Nutricional/métodos , Pancreatite/terapia , Doença Aguda , Consenso , Nutrição Enteral/efeitos adversos , Nutrição Enteral/métodos , Alimentos Formulados , Humanos , Fatores Imunológicos/administração & dosagem , Fatores Imunológicos/uso terapêutico , Pancreatite/complicações , Pancreatite/metabolismo , Nutrição Parenteral/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA